Niven R W, Whitcomb K L, Shaner L, Ip A Y, Kinstler O B
Amgen Inc., Thousand Oaks, CA 91320, USA.
Pharm Res. 1995 Sep;12(9):1343-9. doi: 10.1023/a:1016281925554.
The objective of this study was to highlight differences in the pulmonary absorption of a monoPEGylated rhG-CSF and rhG-CSF after intratracheal instillation and aerosol delivery.
Male Sprague Dawley rats (250 g) were anesthetized and intratracheally instilled (IT) with protein solution or were endotracheally intubated and administered aerosol for 20 min via a Harvard small animal ventilator. A DeVilbiss "Aerosonic" nebulizer containing 5 ml of protein solution at approximately 3 mg/ml was used to generate aerosol. The volume of protein solution deposited in the lung lobes was estimated to be approximately 13 microliters after delivery of Tc-99m HSA solutions. The PEGylated proteins consisted of a 6 kDa (P6) or 12 kDa PEG (P12) linked to the N-terminus of rhG-CSF. rhG-CSF also was administered IT in buffers at pH 4 and pH 7 and in dosing volumes ranging from 100 to 400 microliters. Blood samples were removed at intervals after dosing and the total white blood cell counts (WBC) were determined. Plasma was assayed for proteins by an enzyme immuno assay.
The plasma protein concentration v. time profiles were strikingly different for aerosol v. IT delivery. The Cmax values for rhG-CSF and P12 after aerosol delivery were greater than found after IT (Aerosol: 598 +/- 135 (ng/ml) rhG-CSF; 182 +/- 14 P12 v. IT: 105 +/- 12 rhG-CSF; 65.9 +/- 5 P12). Similarly, Tmax was reached much earlier after aerosol administration (Aerosol: 21.7 +/- 4.8 (min) rhG-CSF; 168 +/- 31 P12 v. IT: 100 +/- 17 rhG-CSF; 310 +/- 121 P12). Estimated bioavailabilities (F(lung)%) were significantly greater via aerosol delivery than those obtained after IT (Aerosol: 66 +/- 14 rhG-CSF; 12.3 +/- 1.9 P12 v. IT: 11.9 +/- 1.5 rhG-CSF; 1.6 +/- 0.1 P12). An increase in circulating WBC counts was induced by all proteins delivered to the lungs. The rate and extent of absorption of rhG-CSF was not influenced by the pH employed nor the instilled volume.
Estimates of bioavailability are dependent upon the technique employed to administer drug to the lungs. Aerosol administration provides a better estimate of the systemic absorption of macromolecules.
本研究的目的是突出单聚乙二醇化重组人粒细胞集落刺激因子(rhG-CSF)和rhG-CSF经气管内滴注和气溶胶给药后肺部吸收的差异。
将雄性Sprague Dawley大鼠(250 g)麻醉,经气管内滴注(IT)蛋白质溶液,或经气管插管,通过哈佛小动物呼吸机给予气溶胶20分钟。使用含有5 ml浓度约为3 mg/ml蛋白质溶液的德维比斯“Aerosonic”雾化器产生气溶胶。在输注99mTc人血清白蛋白(HSA)溶液后,估计沉积在肺叶中的蛋白质溶液体积约为13微升。聚乙二醇化蛋白质由连接到rhG-CSF N端的6 kDa(P6)或12 kDa聚乙二醇(P12)组成。rhG-CSF也在pH 4和pH 7的缓冲液中以100至400微升的给药体积进行气管内滴注。给药后每隔一段时间采集血样,测定总白细胞计数(WBC)。通过酶免疫测定法测定血浆中的蛋白质。
气溶胶给药与气管内滴注给药相比,血浆蛋白浓度随时间变化的曲线显著不同。气溶胶给药后rhG-CSF和P12的Cmax值高于气管内滴注给药(气溶胶:rhG-CSF为598±135(ng/ml);P12为182±14,气管内滴注:rhG-CSF为105±12;P12为65.9±5)。同样,气溶胶给药后达到Tmax的时间要早得多(气溶胶:rhG-CSF为21.7±4.8(分钟);P12为168±31,气管内滴注:rhG-CSF为100±17;P12为310±121)。通过气溶胶给药估计的生物利用度(F(肺)%)显著高于气管内滴注给药(气溶胶:rhG-CSF为66±14;P12为12.3±1.9,气管内滴注;rhG-CSF为11.9±1.5;P12为1.6±0.1)。所有输送到肺部的蛋白质均诱导循环白细胞计数增加。rhG-CSF的吸收速率和程度不受所用pH值或滴注体积的影响。
生物利用度的估计取决于将药物输送到肺部所采用的技术。气溶胶给药能更好地估计大分子的全身吸收情况。